• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom stock rises after hours on Street-beating Q4

February 9, 2023 By Sean Whooley

Dexcom updated logoDexcom (Nasdaq:DXCM) shares ticked up after the market closed today on fourth-quarter results that topped the consensus forecast.

Shares of DXCM rose 2.2% at $109.61 apiece after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 10.1%.

The San Diego-based continuous glucose monitor (CGM) maker posted profits of $91.8 million. That amounts to 22¢ per share on sales of $815.2 million for the three months ended Dec. 31, 2022.

Dexcom recorded a nearly $100 million bottom-line gain out from the red on sales growth of 16.8%.

Adjusted to exclude one-time items, earnings per share totaled 34¢. That landed 7¢ ahead of expectations on Wall Street. Dexcom posted a sales beat, too, as analysts projected sales of $809.7 million.

Dexcom’s Q4 had some big news

Highlights from the quarter included the FDA clearance of the next-generation Dexcom G7 CGM. The company plans to announce the U.S. launch for G7 in a Super Bowl ad this weekend.

Chair, President and CEO Kevin Sayer told Drug Delivery Business News that the company aims to provide CGM for uses beyond diabetes.

“2022 proved to be another great year for Dexcom as we delivered record new customer starts, drove multiple new product launches and significantly expanded access to Dexcom CGM around the world,” Sayer said in a news release. “As we move into 2023, we are very excited to officially bring G7 to the U.S. market and further advance our strategic initiatives to reach the millions of additional people that could benefit from Dexcom CGM.”

Dexcom anticipates revenues between $3.35 billion and $3.49 billion. That amounts to 15%-20% growth over 2022. The company previously attributed its expected growth to increasing CGM awareness and the launch of the G7 in the U.S. Other growth comes from G7’s continued rollout in international markets and further international expansion.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS